Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M79,868Revenue $M25,711Net Margin (%)9.9Z-Score3.0
Enterprise Value $M80,231EPS $2.0Operating Margin %14.4F-Score5
P/E(ttm))13.1Cash Flow Per Share $9.7Pre-tax Margin (%)12.7Higher ROA y-yN
Price/Book1.410-y EBITDA Growth Rate %7.6Quick Ratio1.1Cash flow > EarningsY
Price/Sales3.15-y EBITDA Growth Rate %-9.0Current Ratio1.3Lower Leverage y-yY
Price/Cash Flow5.0y-y EBITDA Growth Rate %-21.6ROA % (ttm)4.6Higher Current Ratio y-yY
Dividend Yield %4.4Insider Buy (3m)0ROE % (ttm)11.0Less Shares Outstanding y-yN
Payout Ratio %137Shares Outstanding M1,252ROI % (ttm)12.6Gross Margin Increase y-yN

Gurus Latest Trades with AZN

Number of guru portfolios checked: 54.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AZNDavid Dreman 2013-12-31 Reduce-0.34%$49.72 - $59.5
($54.28)
$ 63.5317%Reduce -40.32%106,975
AZNJohn Hussman 2013-12-31 Reduce-0.11%$49.72 - $59.5
($54.28)
$ 63.5317%Reduce -58.82%28,000
AZNCharles Brandes 2013-09-30 Add0.12%$47.88 - $52.08
($50.24)
$ 63.5326%Add 7.92%2,381,040
AZNJohn Hussman 2013-09-30 Reduce-0.66%$47.88 - $52.08
($50.24)
$ 63.5326%Reduce -81.87%68,000
AZNJohn Hussman 2013-06-30 Reduce-1.02%$47.22 - $53.01
($50.92)
$ 63.5325%Reduce -59.76%375,000
AZNJoel Greenblatt 2013-06-30 Sold Out -0.24%$47.22 - $53.01
($50.92)
$ 63.5325%Sold Out0
AZNJohn Hussman 2013-03-31 Reduce-0.74%$44.67 - $50.06
($47.4)
$ 63.5334%Reduce -38.8%932,000
AZNCharles Brandes 2012-12-31 Buy 1.2%$44.34 - $48.9
($46.77)
$ 63.5336%New holding, 2188735 sh.2,188,735
AZNJohn Hussman 2012-12-31 Reduce-0.56%$44.34 - $48.9
($46.77)
$ 63.5336%Reduce -24.49%1,523,000
AZNDavid Dreman 2012-12-31 Reduce-0.2%$44.34 - $48.9
($46.77)
$ 63.5336%Reduce -52.4%152,504
AZNJoel Greenblatt 2012-12-31 Reduce-0.12%$44.34 - $48.9
($46.77)
$ 63.5336%Reduce -31.34%83,972
AZNJoel Greenblatt 2012-09-30 Add0.12%$44.91 - $48.35
($46.83)
$ 63.5336%Add 42.7%122,294
AZNCharles Brandes 2012-09-30 Sold Out -1.2%$44.91 - $48.35
($46.83)
$ 63.5336%Sold Out0
AZNDavid Dreman 2012-09-30 Reduce-0.11%$44.91 - $48.35
($46.83)
$ 63.5336%Reduce -24.31%320,376
AZNJoel Greenblatt 2012-03-31 Add0.12%$44.18 - $48.58
($42.78)
$ 63.5348%Add 66.8%74,557
AZNJoel Greenblatt 2011-12-31 Buy 0.25%$42.53 - $49.89
($46.11)
$ 63.5338%New holding, 44699 sh.44,699
AZNJoel Greenblatt 2011-06-30 Sold Out -0.33%$46.6 - $52.4
($50.2)
$ 63.5327%Sold Out0
AZNBruce Berkowitz 2011-06-30 Sold Out -0.05%$46.6 - $52.4
($50.2)
$ 63.5327%Sold Out0
AZNBruce Berkowitz 2011-03-31 Buy 0.05%$45.4 - $49.38
($47.67)
$ 63.5333%New holding, 155000 sh.155,000
AZNJoel Greenblatt 2011-03-31 Reduce-0.35%$45.4 - $49.38
($47.67)
$ 63.5333%Reduce -51.77%23,900
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AZN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
AZN Charles Brandes 2013-12-312,503,8480.21.8+5.16%
AZN David Dreman 2013-12-31106,9750.010.73-40.32%
AZN John Hussman 2013-12-3128,00000.12-58.82%
Premium Most recent portfolio changes are included for Premium Members only!


AZN: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about AZN :

    Quarterly/Annual Reports about AZN:

      News about AZN:

      Articles On GuruFocus.com
      Abbott Capturing Incremental Market Share Mar 18 2014 
      Abbvie's Humira Continues to be a Powerful Catalyst for Growth Mar 18 2014 
      10 British Stocks to Consider Feb 20 2014 
      Bristol-Myers: Don’t Let This One Get Away Jan 15 2014 
      AstraZeneca: Time to Make a Bet? Steven Cohen Seems to Think It Is Jan 15 2014 
      Profits Are Good, Cures Are Better: The Pharmaceutical Industry Oct 08 2013 
      Insiders Are Buying Idera Pharmaceuticals Sep 19 2013 
      For a Healthier Portfolio - Look Here Jul 25 2013 
      My 4 Favorite Dividend Growth Stocks from Abroad May 20 2013 
      My 3 Favorite Foreign Stocks with Cheap Valuation and Great Yields May 15 2013 

      More From Our Partners
      Glaxo's Tanzeum Approved in the U.S. - Analyst Blog Apr 16 2014 - ZACKS

      Add Notes, Comments or Ask Questions

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK
      Hide